Table 1.
Treatment | % ventral | n |
---|---|---|
250 μM aPKCλ MO | 14 | 159 |
2 mM aPKCζ MO | 21 | 188 |
250 μM aPKCλ MO + 2 mM aPKCζ MO | 45 | 142 |
Uninjected | 4 | 260 |
120 pg aPKCλ DN | 16 | 45 |
300 pg aPKCλ DN | 38 | 66 |
aPKCλm567/m567 | 27 | 67 |
aPKCλm567/+ and +/+ | 3 | 192 |
aPKCλm567/m567 with 2 mM aPKCζ MO | 41 | 22 |
aPKCλm567/+ or +/+ with 2 mM aPKCζ MO | 15 | 95 |
pard6gbfh266/fh266 | 50 | 42 |
pard6gbfh266/+ and +/+ | 3 | 156 |
2 mM Lama1 MO | 88 | 16 |
1 mM Lama1 MO | 60 | 86 |
lamininα1uw1/uw1 | 88 | 51 |
DN, Dominant Negative,; MO, morpholino.